Aclaris Therapeutics, Inc. ACRS

Rank #2334 · Nasdaq · $0.6B market cap

⚠ Going-concern flag — the auditor (PricewaterhouseCoopers LLP) raised substantial doubt about this company's ability to continue operating in the latest filing. Read the actual filing before drawing conclusions.

Score

24.0

P/E

-4.2

P/B

3.53

ROE

-84.0%

Op. Margin

-758.2%

Debt Ratio

41%

Health Check — percentile rank within this universe, based on the latest annual filing

Valuation ★☆☆☆☆

Weak

P/E -4.2x, P/B 3.53x. Ranks in the top 73% of the universe.

Profitability ★☆☆☆☆

Poor

ROE -84.0%. Ranks in the top 94% of the universe.

Safety ★★★★☆

Good

Debt ratio 41%. Ranks in the top 21% of the universe. Under 100% is generally considered a safe level.

Growth ★☆☆☆☆

Poor

Revenue decline of 40.1% year over year. Ranks in the top 96% of the universe.

Safety is the relative strength · Valuation is the relative weakness (relative to this universe).

Financials annual, from SEC 10-K filings

FY	Revenue	Op. Income	Net Income	Equity	Op. Margin%	Debt%
2015	–	$-0.0B	$-0.0B	$-0.0B	–	-66
2016	–	$-0.0B	$-0.0B	$-0.0B	–	-17
2017	$0.0B	$-0.0B	$-0.0B	$-0.0B	-1228.0	-32
2018	$0.0B	$-0.0B	$-0.0B	$0.1B	-2885.7	20
2019	$0.0B	$-0.1B	$-0.1B	$0.2B	-3230.0	36
2020	$0.0B	$-0.1B	$-0.1B	$0.2B	-1378.3	13
2021	$0.0B	$-0.1B	$-0.2B	$0.2B	-2627.3	15
2022	$0.0B	$-0.1B	$-0.1B	$0.1B	-785.4	77
2023	$0.0B	$-0.1B	$-0.1B	$0.0B	-1327.1	151
2024	$0.0B	$-0.1B	$-0.1B	$0.2B	-311.6	20
2025	$0.0B	$-0.1B	$-0.1B	$0.2B	-758.2	41

← See the full screener